Roberta Fajka-Boja

Roberta Fajka-Boja

Auto-generated profile, based on publicly available information

Roberta Fajka-Boja

Laboratory of DNA Damage and Nuclear Dynamics, Institute of Genetics, HUN-REN Biological Research Centre, Szeged, Hungary

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2024 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
HMHasan Mamar
Hasan Mamar
RFRoberta Fajka-Boja
Roberta Fajka-Boja
MMMónika Mórocz
Mónika Mórocz
EJEva Pinto Jurado
Eva Pinto Jurado
SZSiham Zentout
Siham Zentout
GTGyula Timinszky
Gyula Timinszky
The clinical success of PARP1/2 inhibitors (PARPi) prompts the expansion of their applicability beyond homologous recombination deficiency. Here, we demonstrate that the loss of the accessory subunits of DNA polymerase epsilon, POLE3 and POLE4, sensitizes cells to PARPi. We show that the sensitivity of POLE4 knockouts is not due to compromised response to DNA damage or homologous recombination deficiency. Instead, POLE4 loss affects replication speed leading to the accumulation of single-stranded DNA gaps behind replication forks upon PARPi treatment, due to impaired post-replicative repair. POLE4 knockouts elicit elevated replication stress signaling involving ATR and DNA-PK. We find POLE4 to act parallel to BRCA1 in inducing sensitivity to PARPi and counteracts acquired resistance associated with restoration of homologous recombination. Altogether, our findings establish POLE4 as a promising target to improve PARPi driven therapies and hamper acquired PARPi resistance.

4 July 2026 in EMBO Reports
Verified
Journal Article
Open access
PDF file
AMAlexandra Mihuț
Alexandra Mihuț
DGDebanjan Ghosh
Debanjan Ghosh
AKAdrián Kószó
Adrián Kószó
DSDávid Szüts
Dávid Szüts
SSSarka Andrs Salajkova
Sarka Andrs Salajkova
GTGyula Timinszky
Gyula Timinszky
Poly(ADP-ribosyl)ation (PARylation) is a transient post-translational modification catalyzed by PARP enzymes and reversed by PARG. PARG inhibition causes sustained PARylation and is being explored as an anticancer strategy, but its cellular consequences remain incompletely understood. Here, we examine how persistent PARylation influences cellular responses to replication stress and DNA damage. We show that sustained PARylation reduces phosphorylated and chromatin-bound RPA most strongly under fork-stalling conditions that progress toward fork collapse. This effect requires PARP1 activity and is restrained by intact ATR–CHK1 signaling, as checkpoint inhibition renders otherwise resistant cells permissive for PARG inhibitor-associated phosphorylated RPA loss from the chromatin. The reduction of RPA phosphorylation is not dependent on BRCA1 and it is not accompanied by increased RAD51 loading. Instead, reduced chromatin-bound RPA coincides with decreased exposed ssDNA. Our results identify a checkpoint-dependent fork-collapse state in which sustained PARylation limits ssDNA and RPA levels.

22 September 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
HMHasan Mamar
Hasan Mamar
RFRoberta Fajka-Boja
Roberta Fajka-Boja
MMMónika Mórocz
Mónika Mórocz
EJEva Pinto Jurado
Eva Pinto Jurado
SZSiham Zentout
Siham Zentout
GTGyula Timinszky
Gyula Timinszky
The clinical success of PARP1/2 inhibitors prompts the expansion of their applicability beyond homologous recombination deficiency. Here, we demonstrate that the loss of the accessory subunits of DNA polymerase epsilon, POLE3 and POLE4, sensitizes cells to PARP inhibitors. We show that the sensitivity of POLE4 knockouts is not due to a compromised response to DNA damage or homologous recombination deficiency. Instead, POLE4 deletion generates replication stress with the accumulation of single-stranded DNA gaps upon PARP inhibitor treatment. In POLE4 knockouts, replication stress leads to elevated DNA-PK signaling revealing a role of POLE4 in regulating DNA-PK activation. Moreover, POLE4 knockouts show synergistic sensitivity to the co-inhibition of ATR and PARP. Finally, POLE4 loss enhances the sensitivity of BRCA1-deficient cells to PARP inhibitors and counteracts acquired resistance consecutive to restoration of homologous recombination. Altogether, our findings establish POLE4 as a promising target to improve PARP inhibitor driven therapies and hamper acquired PARP inhibitor resistance.